Special Report: You Could Lose or Make a Fortune

Todd Campbell

Todd Campbell

TMFEBCapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent articles

GettyImages-1138911813

Why Co-Diagnostics Skyrocketed 28.3% Today

The FDA has approved emergency use of its at-home COVID-19 test.


GettyImages-874899136

Why Alector Is Tumbling 28.7% Today

Investors appear nervous that COVID-19 precautions could create obstacles to trials evaluating its lead drug candidate.


GettyImages-1089374276

Why Medpace Holdings Is Skyrocketing 13.5% Higher Today

The clinical trial company's second-quarter financial results were better than expected.


GettyImages-1186545957

Jazz Pharmaceuticals Wins FDA Approval for Its New Narcolepsy Drug

Xywav has been shown to reduce both cataplexy and excessive daytime sleepiness in narcolepsy patients.


GettyImages-1138911813

Why CytoSorbents Is Soaring 12% Today

The company has priced its recently announced stock offering.

GettyImages-996828576

Gilead Sciences Invests $300 Million in an Immuno-Oncology Startup

The biopharma giant is acquiring 49.9% of privately-held Tizona Therapeutics.


GettyImages-1205778418

Here's Why OPKO Health's Stock Is Skyrocketing 23% Today

The company confirmed it will provide coronavirus testing for the National Football League.


GettyImages-910148024

Here's Why Tricida Is Tanking 38.5% Today

The FDA has noted deficiencies in the application for approval of its only drug in development.


GettyImages-996828576

Why Waters Stock Is Skyrocketing 12.9% Today

The healthcare company's second-quarter results appear better than expected.


vaccine

Here's Why Dynavax Is Surging 6.1% Today

Enrollment has begun in an early stage coronavirus vaccine trial utilizing Dynavax's technology.

GettyImages-637107694

Blueprint Medicines Inks Deal With Roche Worth Up to $1.7 Billion

Roche is licensing commercial rights to Blueprint Medicines RET-inhibitor pralsetinib.


GettyImages-1138911813

Why InMode Shares Are Soaring 13.7% Today

The medical device maker's boosting its second-quarter guidance.


GettyImages-1178374751

Here's Why Retractable Technologies Is Skyrocketing 22% Today

The company's been awarded a multimillion-dollar government COVID-19 contract to expand production of needles and syringes.


GettyImages-1212440479

GlaxoSmithKline Inks New COVID-19 Vaccine Research Pact

Medicago is using GlaxoSmithKline's vaccine adjuvant in its clinical-stage COVID-19 vaccine.


GettyImages-637107694

Turning Point Therapeutics Licenses Its Lung Cancer Drug in China

Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.

GettyImages-910148024

Why Bellus Health Stock Tanked 69.2% Today

The company's lead drug has failed a phase 2 trial.


GettyImages-874899136

Why MEI Pharma Is Tanking 15.3% Today

A trial evaluating its most advanced drug has been discontinued because of a lack of efficacy.


GettyImages-1141354730

Why COVID-19 Vaccine Developer Dynavax Is Down 6.5% Today

Pfizer released intriguing data regarding its own COVID-19 vaccine.


GettyImages-1179979986

Why Translate Bio Crashed 21% Today

The clinical-stage vaccine developer, which is working on a COVID-19 vaccine candidate, announced it's selling more shares to the public.


GettyImages-1141354730

uniQure Inks $2 Billion Licensing Deal With CSL Behring

Agreement licenses the rights for a promising hemophilia B gene therapy.